M. Duvic and J. Vu, Vorinostat: A New Oral Histone Deacetylase Inhibitor Approved for Cutaneous T-Cell Lymphoma, Expert Opin. Investig. Drugs, vol.16, 1111.

R. Poole, Belinostat: First Global Approval. Drugs, vol.74, pp.1543-1554, 2014.

M. P. Fenichel and . Fda, Approves New Agent for Multiple Myeloma, J. Natl. Cancer Inst, p.165, 2015.

C. Grant, F. Rahman, R. Piekarz, C. Peer, R. Frye et al., Romidepsin: A New Therapy for Cutaneous T-Cell Lymphoma and a Potential Therapy for Solid Tumors, Expert Rev. Anticancer Ther, vol.10, pp.997-1008, 2010.

Y. Shi, B. Jia, W. Xu, W. Li, T. Liu et al., Chidamide in Relapsed or Refractory Peripheral T Cell Lymphoma: A Multicenter Real-World Study in China. J. Hematol. Oncol.J. Hematol Oncol, vol.10, p.69, 2017.

N. Azad, C. A. Zahnow, C. M. Rudin, and S. B. Baylin, The Future of Epigenetic Therapy in Solid Tumours: Lessons from the Past, Nat. Rev. Clin. Oncol, vol.10, pp.256-266, 2013.

C. H. Arrowsmith, C. Bountra, P. V. Fish, K. Lee, and M. Schapira, Epigenetic Protein Families: A New Frontier for Drug Discovery, Nat. Rev. Drug Discovery, vol.11, pp.384-400, 2012.

D. Feng, J. Wu, Y. Tian, H. Zhou, Y. Zhou et al., Targeting of Histone Deacetylases to Reactivate Tumour Suppressor Genes and Its Therapeutic Potential in a Human Cervical Cancer Xenograft Model, PLoS One, vol.8, issue.e80657, 2013.

T. Wagner, P. Brand, T. Heinzel, and O. H. Kramer, Histone Deacetylase 2 Controls P53 and Is a Critical Factor in Tumorigenesis, Biochim. Biophys. Acta, Rev. Cancer, pp.524-538, 1846.

Y. Ma, H. Jin, X. Wang, V. Y. Shin, D. Chen et al., Histone Deacetylase 3 Inhibits New Tumor Suppressor Gene DTWD1 in Gastric Cancer, Am. J. Cancer Res, vol.5, pp.663-673, 2015.

M. Mottamal, S. Zheng, L. T. Huang, and G. Wang, Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents, Molecules, vol.20, p.3898, 2015.

J. Roche and P. Bertrand, Inside HDACs with More Selective HDAC Inhibitors, Eur. J. Med. Chem, vol.121, pp.451-483, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01505640

R. W. Robey, A. R. Chakraborty, A. Basseville, V. Luchenko, J. Bahr et al., Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance, Mol. Pharmaceutics, 2011.

P. Hermant, D. Bosc, C. Piveteau, R. Gealageas, B. Lam et al., Deprez-Poulain, R. Controlling Plasma Stability of Hydroxamic Acids: A MedChem Toolbox, J. Med. Chem, vol.60, pp.9067-9089, 2017.

O. Witt, H. E. Deubzer, T. Milde, I. Oehme, and . Family, What Are the Cancer Relevant Targets?, Cancer Lett, pp.277-285, 2009.

J. C. Bressi, A. J. Jennings, R. Skene, Y. Wu, R. Melkus et al., Exploration of the HDAC2 Foot Pocket: Synthesis and {SAR} of Substituted N-(2-Aminophenyl)Benzamides, Bioorg. Med. Chem. Lett, pp.3142-3145, 2010.

G. Estiu, E. Greenberg, C. B. Harrison, N. P. Kwiatkowski, R. Mazitschek et al., Structural Origin of Selectivity in Class II-Selective Histone Deacetylase Inhibitors, J. Med. Chem, vol.51, 2008.

V. Zwick, A. Nurisso, C. Simo?s-pires, S. Bouchet, N. Martinet et al., Cross Metathesis with Hydroxamate and Benzamide BOC-Protected Alkenes to Access {HDAC} Inhibitors and Their Biological Evaluation Highlighted Intrinsic Activity of BOC-Protected Dihydroxamates, Bioorg. Med. Chem. Lett, vol.26, pp.154-159, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01299475

P. Bertrand, Inside HDAC with HDAC Inhibitors, Eur. J. Med. Chem, p.45, 2010.
URL : https://hal.archives-ouvertes.fr/hal-01505640

S. Valente, D. Trisciuoglio, T. De-luca, A. Nebbioso, D. Labella et al., 1,3,4-Oxadiazole-Containing Histone Deacetylase Inhibitors: Anticancer Activities in Cancer Cells, J. Med. Chem, vol.57, pp.6259-6265, 2014.

M. D. Shultz, X. Cao, C. H. Chen, Y. S. Cho, N. R. Davis et al., Optimization of the in Vitro Cardiac Safety of Hydroxamate-Based Histone Deacetylase Inhibitors, J. Med. Chem, vol.54, pp.4752-4772, 2011.

W. Tang, T. Luo, E. F. Greenberg, J. E. Bradner, and S. L. Schreiber, Discovery of Histone Deacetylase 8 Selective Inhibitors, Bioorg. Med. Chem. Lett, 2011.

C. Blanquart, M. Francois, C. Charrier, P. Bertrand, and M. Gre?oire, Pharmacological Characterization of Histone Deacetylase Inhibitor and Tumor Cell-Growth Inhibition Properties of New Benzofuranone Compounds, Curr. Cancer Drug Targets, vol.11, pp.919-928, 2011.

R. Delatouche, I. Denis, M. Grinda, F. El-bahhaj, E. Baucher et al., Design of PH Responsive Clickable Prodrugs Applied to Histone Deacetylase Inhibitors: A New Strategy for Anticancer Therapy, Eur. J. Pharm. Biopharm, vol.85, pp.862-72, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01006764

T. Ohira, R. M. Gemmill, K. Ferguson, S. Kusy, J. Roche et al., WNT7a Induces E-Cadherin in Lung Cancer Cells, Proc. Natl. Acad. Sci. U. S. A, vol.100, pp.10429-10434, 2003.

V. A. Potiron, J. Roche, and H. A. Drabkin, Semaphorins and Their Receptors in Lung Cancer, Cancer Lett, vol.273, pp.1-14, 2009.

T. Abbas and A. Dutta, P21 in Cancer: Intricate Networks and Multiple Activities, Nat. Rev. Cancer, vol.9, pp.400-414, 2009.

C. Hubbert, A. Guardiola, R. Shao, Y. Kawaguchi, A. Ito et al., HDAC6 Is a Microtubule-Associated Deacetylase, Nature, vol.417, pp.455-458, 2002.

T. U. Bracker, A. Sommer, I. Fichtner, H. Faus, B. Haendler et al., Efficacy of MS-275, a Selective Inhibitor of Class I Histone Deacetylases, in Human Colon Cancer Models, Int. J. Oncol, vol.35, pp.909-920, 2009.

Y. Hai and D. W. Christianson, Histone Deacetylase 6 Structure and Molecular Basis of Catalysis and Inhibition, Nat. Chem. Biol, vol.12, pp.741-747, 2016.

J. Zhou, M. Li, N. Chen, S. Wang, H. Luo et al., Computational Design of a Time-Dependent Histone Deacetylase 2 Selective Inhibitor, ACS Chem. Biol, vol.10, pp.687-692, 2015.

Y. Miyake, J. J. Keusch, L. Wang, M. Saito, D. Hess et al., Structural Insights into HDAC6 Tubulin Deacetylation and Its Selective Inhibition, Nat. Chem. Biol, vol.12, pp.748-754, 2016.

S. Schafer, L. Saunders, E. Eliseeva, A. Velena, M. Jung et al., Phenylalanine-Containing Hydroxamic Acids as Selective Inhibitors of Class IIb Histone Deacetylases (HDACs), Bioorg. Med. Chem, vol.16, 2008.